KAIST Team Reprograms Colon Cancer Cells into Normal Cells; Study Finds Anti-TNF Drugs Safe for Rheumatoid Arthritis-Associated Lung Disease

A team led by Professor Kwang-Hyun Cho at KAIST in South Korea has discovered a method to convert colon cancer cells into normal cells. This innovative approach uses digital twin technology to simulate gene interactions, identifying key molecules that trigger this transformation. Unlike traditional cancer treatments that kill cancer cells and often cause severe side effects, this method offers a potentially safer alternative. Further research could revolutionize cancer treatment by shifting the focus from destruction to restoration. Separately, a U.S. study published in The Lancet Rheumatology indicates that anti-TNF drugs are as safe as other biological or synthetic drugs for patients with rheumatoid arthritis-associated interstitial lung disease (ILD-AR). The study found no significant differences in treatment outcomes between patients treated with anti-TNF drugs and those treated with other therapies. This suggests that anti-TNF drugs do not need to be systematically avoided in ILD-AR patients and can be a valid treatment option.